Article citationsMore>>

Tan, D.S., Yom, S.S., Tsao, M.S., Pass, H.I., Kelly, K., Peled, N., Yung, R.C., Wistuba, I.I., Yatabe, Y., Unger, M., et al. (2016) The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-positive Non-small-cell Lung Cancer: Status in 2016. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer, 11, 946-963.

has been cited by the following article:

• TITLE: The Impact of Chemotherapy on EGFR Mutation Status in Non-Small-Cell Lung Cancer: A Meta-Analysis

  AUTHORS: Xiaoshun Shi, Fuxi Huang, Allen M. Chen, Zhuolin Wu, Qianqian Huang, Ying Liang, Qipeng Zhou, Haiyun Mo, Xiaoxiang Li, Jiexia Zhang

  KEYWORDS: EGFR Mutation, Chemotherapy, Non-Small Cell Lung Cancer, Me-ta-Analysis

  JOURNAL NAME: Open Journal of Genetics, Vol.7 No.4, December 21, 2017

  ABSTRACT: Background: Emerging evidence indicates that chemotherapy for lung cancer may alter EGFR mutation status. However, whether chemotherapy as a firstline treatment may increase or reduce the frequency of EGFR mutations in NSCLC remains uncertain. Therefore, we conducted a meta-analysis to evaluate whether chemotherapy leads to altered EGFR mutation status. Methods: A systematic literature search was performed using the PubMed, OVID, Science Direct, Cochrane Library, and CNKI databases for studies on pre- and post-chemotherapy EGFR mutation status. Relevant studies documenting perichemotherapy EGFR mutation ratios were included. Analyses of pooled odds ratios (OR) were performed. Results: Six studies involving 656 patients were included in this meta-analysis. It was found that chemotherapy may alter EGFR status (OR = 1.93, 95% CI 1.05 - 3.56; p Conclusions: Chemotherapy may contribute to altered EGFR status. NSCLC patients with EGFR mutations might need to be considered for EGFR status redeterminations prior to second-line EGFR-TKI treatment or upon tumor recurrence after chemotherapy. Further randomized clinical trials should investigate the impact of neoadjuvant or first-line chemotherapy on EGFR mutation status in NSCLC patients.